Targeting the MDM2–p53 Protein–Protein Interaction for New Cancer Therapy: Progress and Challenges

Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End

(2016) Amanda R. Wasylishen et al.   Cold Spring Harbor Perspectives in Medicine

The Role of MDM2 Amplification and Overexpression in Tumorigenesis

(2016) Jonathan D. Oliner et al.   Cold Spring Harbor Perspectives in Medicine

Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia In Vitro and In Vivo

(2015) C. G. Hoffman-Luca et al.   CLINICAL CANCER RESEARCH

Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors

(2015) Philipp Holzer et al.   JOURNAL OF MEDICINAL CHEMISTRY

SAR405838: An Optimized Inhibitor of MDM2-p53 Interaction That Induces Complete and Durable Tumor Regression

(2014) S. Wang et al.   CANCER RESEARCH

Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development

(2014) Daqing Sun et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development

(2013) Qingjie Ding et al.   JOURNAL OF MEDICINAL CHEMISTRY

A Potent Small-Molecule Inhibitor of the MDM2–p53 Interaction (MI-888) Achieved Complete and Durable Tumor Regression in Mice

(2013) Yujun Zhao et al.   JOURNAL OF MEDICINAL CHEMISTRY

Diastereomeric Spirooxindoles as Highly Potent and Efficacious MDM2 Inhibitors

(2013) Yujun Zhao et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development

(2013) Binh Vu et al.   ACS Medicinal Chemistry Letters

Structure-Based Design of Novel Inhibitors of the MDM2–p53 Interaction

(2012) Yosup Rew et al.   JOURNAL OF MEDICINAL CHEMISTRY

Ordering of the N-Terminus of Human MDM2 by Small Molecule Inhibitors

(2012) Klaus Michelsen et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

(2012) Isabelle Ray-Coquard et al.   LANCET ONCOLOGY

Detection of MDM2 gene amplification or protein expression distinguishes sclerosing mesenteritis and retroperitoneal fibrosis from inflammatory well-differentiated liposarcoma

(2008) Joshua Weaver et al.   MODERN PATHOLOGY

Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasms

(2008) Joshua Weaver et al.   MODERN PATHOLOGY